CIAM
MLYS icon

Caitong International Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

Caitong International Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$486 Buy
+18
New +$494 ﹤0.01% 1740
2026
Q1 		– Sell
-3,823
Closed -$139K – 2873
2025
Q4 		$139K Buy
3,823
+3,715
+3,440% +$149K 0.03% 310
2025
Q3 		$4.09K Sell
108
-84
-44% -$1.82K ﹤0.01% 1272
2025
Q2 		$2.6K Buy
+192
New +$2.78K ﹤0.01% 1295

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Caitong International Asset Management's MLYS Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 18 shares worth $486. The stake represents ﹤0.01% of the portfolio and ranks #1740 among its holdings. This is a return to the name: Caitong International Asset Management previously reported a position in MLYS as recently as Q4 2025.

Caitong International Asset Management first reported a position in MLYS in Q2 2025 and has held it in 4 quarters since. The position peaked at $139K in Q4 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Caitong International Asset Management held 18 shares of Mineralys Therapeutics worth $486 as of Q2 2026.
  • Mineralys Therapeutics was a new Caitong International Asset Management position in Q2 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1740 holding.
  • Caitong International Asset Management first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Caitong International Asset Management's Mineralys Therapeutics position peaked at $139K in Q4 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.